[Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis]

Primary biliary cholangitis (PBC) is an autoimmune-mediated chronic cholestatic liver disease. Ursodeoxycholic acid (UDCA) is a first-line drug approved by the Food and Drug Administration for the treatment of PBC. It can effectively improve serum biochemical indicators, delay histological progress, and prolong the survival of non-transplant patients. However, around 40% of patients with PBC have a poor response to UDCA with a poor outcome. Early identification of patients with poor biochemical responses and timely second-line treatment may alter the course of the disease. This article summarizes the risk factors for the poor response of UDCA in the PBC.